EBR Systems Receives Final Approval for NTAP Reimbursement; Shares Up 7%

MT Newswires Live
2025/08/05

EBR Systems (ASX:EBR) said the US Centers for Medicare & Medicaid Services confirmed approval for its Wireless Stimulation Endocardially for Cardiac Resynchronization Therapy (WiSE CRT) System under the New Technology Add-On Payment (NTAP) scheme for Medicare inpatients, according to a Tuesday filing with the Australian bourse.

The confirmation ensures a maximum reimbursement rate of up to $41,145, based on an average WiSE selling price of $63,300, in addition to Diagnosis Related Group payments for procedure and device costs, the filing said.

The NTAP reimbursement will remain in effect for three years, according to the filing.

Shares rose more than 7% in morning trade on Tuesday.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10